AbbVie Inc (ABBV)vsCG Oncology, Inc. Common stock (CGON)
ABBV
AbbVie Inc
$227.23
-2.69%
HEALTHCARE · Cap: $380.57B
CGON
CG Oncology, Inc. Common stock
$53.72
-4.23%
HEALTHCARE · Cap: $5.25B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 1238689% more annual revenue ($62.82B vs $5.07M). ABBV leads profitability with a 5.8% profit margin vs 0.0%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
CGON
Avoid34
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-55.6%
Fair Value
$146.00
Current Price
$227.23
$81.23 premium
Intrinsic value data unavailable for CGON.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Generating 3.6B in free cash flow
Revenue surging 1983.0% year-over-year
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
0.0% earnings growth
0.0% margin — thin
Weak financial health signals
ROE of -17.1% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.59 suggests the stock is reasonably priced for its growth.
Bull Case : CGON
The strongest argument for CGON centers on Revenue Growth, Debt/Equity, Altman Z-Score. Revenue growth of 1983.0% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 105.1x leaves little room for execution misses.
Bear Case : CGON
The primary concerns for CGON are EPS Growth, Profit Margin, Piotroski F-Score.
Key Dynamics to Monitor
ABBV profiles as a value stock while CGON is a hypergrowth play — different risk/reward profiles.
CGON carries more volatility with a beta of 0.31 — expect wider price swings.
CGON is growing revenue faster at 1983.0% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 34/100) and 12.4% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
CG Oncology, Inc. Common stock
HEALTHCARE · BIOTECHNOLOGY · USA
CG Oncology, Inc. is a clinical-stage biotechnology firm focused on developing pioneering cancer therapies, particularly through its lead product, CG0070, an oncolytic virus therapy designed for non-muscle invasive bladder cancer. Committed to addressing significant unmet medical needs in the oncology space, the company is well-positioned to enhance patient outcomes and transform existing treatment paradigms. As CG Oncology progresses through clinical trials and regulatory processes, its proprietary technology platform sets it apart in the competitive oncology landscape, presenting compelling investment opportunities for institutional investors keen on advancing innovations that may substantially influence cancer care.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?